Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36774933

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2023 Mar 11
First author
Motzer RJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 Mar 11;401(10379):796-798. doi: 10.1016/S0140-6736(22)02631-9.
    note
    Source null
    related pmid
    36774931
    relationship
    Comment in

Authors and identifiers

  1. name
    Motzer RJ
    type
    Author
  2. name
    Russo P
    type
    Author
  3. name
    Grünwald V
    type
    Author
  4. name
    Tomita Y
    type
    Author
  5. name
    Zurawski B
    type
    Author
  6. name
    Parikh O
    type
    Author
  7. name
    Buti S
    type
    Author
  8. name
    Barthélémy P
    type
    Author
  9. name
    Goh JC
    type
    Author
  10. name
    Ye D
    type
    Author
  11. name
    Lingua A
    type
    Author
  12. name
    Lattouf JB
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Motzer RJ
    type
    Author
  2. name
    Russo P
    type
    Author
  3. name
    Grünwald V
    type
    Author
  4. name
    Tomita Y
    type
    Author
  5. name
    Zurawski B
    type
    Author
  6. name
    Parikh O
    type
    Author
  7. name
    Buti S
    type
    Author
  8. name
    Barthélémy P
    type
    Author
  9. name
    Goh JC
    type
    Author
  10. name
    Ye D
    type
    Author
  11. name
    Lingua A
    type
    Author
  12. name
    Lattouf JB
    type
    Author
bibliography ids
  1. nci-bib-4ecbbca521b064a0dae42e37
book metadata
content sha256
bbf14db583a9fd7b133f056b85fefe5e62bce439fa5902d3d3a7b66776a2cd3a
document type
citation
dois
  1. 10.1016/S0140-6736(22)02574-0
electronic publication date
display
2023 Feb 9
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:36774933
immutable id
pubmed:36774933@bbf14db583a9fd7b133f056b85fefe5e62bce439fa5902d3d3a7b66776a2cd3a
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10379
name
Lancet (London, England)
nlm unique id
2985213R
pages
821-832
volume
401
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 Mar 11;401(10379):796-798. doi: 10.1016/S0140-6736(22)02631-9.
    note
    Source null
    related pmid
    36774931
    relationship
    Comment in
outcomes validated
false
pmid
36774933
provenance
batch id
d370e99271168e8a8a13
provider
NCBI PubMed ESummary
record sha256
ea845e3da5cb2a417553af397aaf1f328ffa86f4ba6c3be19806be93ed756cf3
response sha256
f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
retrieved at
2026-09-09T23:48:13.005737+00:00
publication date
display
2023 Mar 11
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36774933/
title
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.

Preserved source evidence · Not medical advice